A process for preparing tumor-specific CTL cells
By optimizing the preparation process of CTL cells, including co-culture of sorted CD8+ cells and artificial antigen presenting cells, the use of IL-2 and IL-7, as well as multiple stimulation and cell fluid replacement, the CTL cells in the prior art were solved. The problem of low purity and viability in the preparation process improves the killing ability and safety of lung cancer-specific CTL cells.
Patent Information
- Application Number
- CN202210489217.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-05-07
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-05-07
AI Technical Summary
In the prior art, CTL cell preparation process has problems such as low purity and activity rate and insufficient target killing ability. In particular, the incubation conditions and optimal determination of the cytokine concentration of antigen presenting cells are difficult to achieve, and mitomycin residues may be Affects product safety.
A method for preparing tumor-specific CTL cells was designed. By sorting CD8+ cells from human peripheral blood mononuclear cells, using highly induced artificial antigen presenting cells and lung cancer antigen peptides, IL-2 and IL- 7. Perform multiple stimulation and cell fluid replacement, optimize cell expansion conditions to improve the purity and viability of CTL cells, and determine lung cancer-specific antigen peptides through bioinformatics analysis to ensure targeted killing ability.
The preparation of lung cancer-specific CTL cells with high purity and high viability rates has been achieved, which significantly improves the killing ability of tumor target cells, reduces non-specific killing, and avoids the risk of mitomycin residue.
Smart Images

Figure BDA0003630930700000031 
Figure BDA0003630930700000041 
Figure HDA0003630930710000011
Abstract
Description
Technical Field
[0001] The present invention relates to the field of immune cell therapy, and in particular to a process for preparing tumor-specific CTL cells. Background Art
[0002] Immune cell therapy is a treatment method that uses the body's own or donor-derived immune cells, which are cultured, expanded or activated in vitro and then returned to the patient's body to stimulate or enhance the body's immune function, thereby clearing abnormal cells such as tumor cells, pathogens or viral infections. Cytotoxic T lymphocytes (CTLs) come from CD8+T cells in white blood cells. They are a type of CTL cell that becomes antigen-specific after activation and induction. They can secrete various cytokines to participate in immune effects, and then kill target cells efficiently and specifically without damaging normal tissues. The advantage of CTL cell therapy is that it is multi-targeted, safe and effective, and is an effective tool for treating solid tumors. CTLs come from CD8+T cells, which are activated by antigen-presenting cells loaded with antigens. In the presence of cytokines, the activated CD8+T cells further expand and differentiate into effector cells or memory cells. Effector cells kill infected cells or cancer cells directly or indirectly.
[0003] A bottleneck technology for CTL preparation is the need for efficient antigen presenting cells. The invention patent with the authorization announcement number CN103667189B has disclosed our previous technology: using artificial fruit fly antigen presenting cell lines to load tumor antigen peptides to activate and induce CD8+T cells, and producing tumor-specific CTL cells after in vitro culture. Tumor-specific CTL cells are effective in tumor treatment and have many potential applications. However, the concentration of antigen peptides used for incubating antigen presenting cells, the ratio of co-culture of CD8+T cells and antigen presenting cells loaded with antigen peptides, the concentration of IL-2 and IL-7 used, and the time of addition all need to determine the optimal conditions, and the process of cell preparation needs to be optimized to ensure that the prepared CTL cells have no specific killing or reduce nonspecific killing. In addition, in the invention, the trophoblast cells that stimulate CTL cells are inactivated with mitomycin when T cells are heavily stimulated twice, but the final CTL product may have the risk of mitomycin residues. Summary of the invention
[0004] The purpose of the present invention is to overcome the deficiencies of the prior art and to design a CTL cell preparation process with high purity and viability and strong targeted killing ability.
[0005] In order to achieve the above object, a method for preparing tumor-specific CTL cells is designed, which is characterized by the following method:
[0006] D0: Prepare the highly efficient induced artificial antigen presenting cell line 1120 from the established working cell bank, and select CD8 cells and Non-CD8 PBMC cells from human peripheral blood mononuclear cells by magnetic beads;
[0007] Artificial antigen presenting cells and lung cancer antigen peptides were co-incubated on D0, and CD8 cells and artificial antigen presenting cells loaded with lung cancer antigen peptides were co-cultured on D0-D4;
[0008] D5 added IL-2 and IL-7;
[0009] Non-CD8 PBMC cells loaded with lung cancer antigen peptides at D7 and D14 restimulated CTL cells;
[0010] During cell expansion from D7 to D20, the cell medium was changed, and IL-2 and IL-7 were added to maintain their growth;
[0011] CTL cells were collected on D20, stained and counted, and the number of live cells and dead cells was recorded.
[0012] Preferably, the expression of major related molecules of the artificial antigen presenting cells is above 50%.
[0013] Preferably, the HLA-A2 expression of the human peripheral blood mononuclear cells is above 50%.
[0014] Preferably, the ratio of CD8 cells and artificial antigen presenting cells loaded with lung cancer antigen peptides co-cultured on D0-D4 is 10:1.
[0015] Preferably, no IL-2 is added from D0 to D4.
[0016] Preferably, the concentration of lung cancer antigen peptide loaded by D0 artificial antigen presenting cells is 0.1 μg / ml.
[0017] Preferably, the concentration of lung cancer antigen peptide loaded on Non-CD8 PBMC cells for restimulation on D7 and D14 is 1 μg / ml.
[0018] Preferably, the Non-CD8 PBMC cells used for restimulation on D7 and D14 do not need to be treated with MMC.
[0019] Preferably, the final concentration of IL-2 added on D5 is 20 IU / ml.
[0020] Preferably, the final concentration of IL-7 added on D5 is 30 U / ml.
[0021] Preferably, IL-2 is added during cell expansion from D7 to D20 to maintain T cell growth at a concentration of 20 IU / ml.
[0022] Preferably, IL-7 is added during D7-D20 cell expansion to maintain T cell growth at a concentration of 30 U / ml.
[0023] Compared with the prior art, the present invention improves and perfects various conditions for preparing CTL cells and determines the preparation process of CTL cells. The lung cancer-specific CTL cells prepared by efficient induction have high purity and viability, strong cell activity, and can effectively kill tumor target cells (by measuring IFN-γ secreted by T cells). DETAILED DESCRIPTION
[0024] The following is a detailed description of an embodiment of the present invention. This embodiment is implemented on the premise of the technical solution of the present invention, and a detailed implementation method and a specific operation process are given, but the protection scope of the present invention is not limited to the following embodiment.
[0025] In the following examples, unless otherwise specified, raw materials, products or processing techniques are conventional commercial products or conventional processing techniques in the art.
[0026] 1. No need to add IL-2 in the first 5 days of CTL preparation
[0027] A 14-day CD8 cell activation and expansion experiment was conducted by comparing the addition of IL-2 (final concentration 20 IU / ml) on Day 0, Day 1, Day 2, Day 3, and Day 4 respectively, and no IL-2 was added on Day 5 for the first 4 days. According to the percentage of CD3+CD8+CD56-, CD95+CD45RA-CD27-CCR7- phenotype expression in the obtained CTL cells, and the targeted killing effect of CTL on T2 cells (loaded with lung cancer antigen peptides), it was concluded that Day 5 was the best time to add IL-2.
[0028] 1.1 Preparation of cells and peptides
[0029] (a) Identification and preparation of peptides
[0030] Using bioinformatics methods, we analyzed the antigenic peptides in lung cancer-specific antigen molecules and determined that there were 8 peptides that could bind to MHC class I molecules. We synthesized these peptides in vitro to ensure a purity of more than 95%. The sequences of the 8 lung cancer antigen peptides are as follows:
[0031]
[0032]
[0033] (b) Artificial antigen presenting cells
[0034] Based on Drosophila SC2, human HLA-A2, CD80, CD54, CD70 and LFA-3 molecules were co-transfected and expressed, and the 1120 strains (hereinafter referred to as D1120 cells) obtained by screening stably expressed these protein molecules. D1120 working cell banks were prepared, and flow cytometry (hereinafter referred to as FACS) was used to determine that the expression of major related molecules was above 50%.
[0035] (c) H1299-A2 cells
[0036] H1299 cells were transformed with pCDNA3.1-A2 plasmid, and after G418 screening, H1299 cell line expressing human HLA-A2 was obtained, named H1299-A2 cells. FACS detection confirmed that HLA-A2 expression was above 50%.
[0037] 1.2 Experimental procedures
[0038] CTL cell culture medium: 2% autologous plasma + 98% CTS TM AIM-V TM Medium.
[0039] (a) Day 0, separation and purity analysis of CD8 cells
[0040] PBMCs were separated from normal human blood using Ficoll, and FACS confirmed that the expression of HLA-A2 in PBMCs was above 50%. CD8 cells and Non-CD8 PBMCs were separated using magnetic beads coupled to anti-human CD8 antibodies, and three Non-CD8 PBMCs were frozen. FACS detected that the percentage of CD14+ expression in Non-CD8 PBMCs was 15.2%, and the percentages of CD3+, CD8+, CD3+CD8+CD56-, CD95-CD45RA+CD27+CCR7+, CD95+CD45RA+CD27+CCR7+, CD95+CD45RA-CD27+CCR7+, CD95+CD45RA-CD27+CCR7-, CD95+CD45RA+CD27-CCR7- in CD8 cells were 98.2%, 98.2%, 94.5%, 19.1%, 0%, 0%, 0%, 0%, 0%, respectively.
[0041] (b) Day 0, incubation of D1120 cells and lung cancer antigen peptides
[0042] Thaw the frozen D1120 working cells and add Expressive Five SFM to adjust the cell density to 1×10 7 / ml, added 8 lung cancer antigen peptides with a final concentration of 0.1μg / ml and β2M protein with a final concentration of 5μg / ml, and incubated at room temperature for 2h.
[0043] (c) Day 0, co-culture of CD8 cells and D1120 cells (loaded with lung cancer antigen peptide)
[0044] CD8 cells and D1120 cells (loaded with lung cancer antigen peptides) were co-cultured at a ratio of 10:1, and CTL cell culture medium was added until the CD8 cell density reached 1×10 6 / ml. There were 6 groups in total, with 2 replicates in each group, named IL-2-D0 group, IL-2-D1 group, IL-2-D2 group, IL-2-D3 group, IL-2-D4 group, and IL-2-D5 group, in which IL-2-D0 group was added with IL-2 (final concentration 20 IU / ml). Cultured in a 37°C, 5% CO2 incubator.
[0045] (d) Day 1-Day 4, add IL-2 according to the group
[0046] IL-2 (final concentration 20 IU / ml) was added to the IL-2-D1 group on Day 1, the IL-2-D2 group on Day 2, the IL-2-D3 group on Day 3, and the IL-2-D4 group on Day 4.
[0047] (e) Day 5, addition of IL-2 and IL-7
[0048] The cells in the IL-2-D0 group were collected, counted, and added into CTL cell culture medium until the cell density reached 0.5×10 6 / ml, IL-2 (final concentration 20 IU / ml) and IL-7 (final concentration 30 U / ml) were added. The other 5 groups were directly added with IL-2 (final concentration 20 IU / ml) and IL-7 (final concentration 30 U / ml).
[0049] (f) Day 6, cell culture medium replacement in IL-2-D1 group
[0050] Collect the cells, count them, and add CTL cell culture medium to a cell density of 0.5×10 6 / ml, add IL-2 (final concentration 20IU / ml) and IL-7 (final concentration 30U / ml).
[0051] (g) Day 7 (Non-CD8 PBMC cell stimulation)
[0052] Inactivation of Non-CD8 PBMC cells: Resuscitate 1 tube of Non-CD8 PBMC cells, add RPMI Medium Modified to resuspend the cells, centrifuge and change the medium, wash twice. Add CTL cell culture medium to a cell density of 5×10 6 / ml, add mitomycin at a final concentration of 10μg / ml, incubate at 37℃ for 20min, resuspend the cells in RPMI Medium Modified, centrifuge to change the medium, and wash three times.
[0053] Incubation of non-CD8 cells with antigen peptides: Add CTL cell culture medium to a cell density of 1×10 7 / ml, added 8 lung cancer antigen peptides with a final concentration of 5μg / ml and β2M protein with a final concentration of 5μg / ml, and incubated at 37℃ for 1.5h.
[0054] CTL cell culture medium replacement: Collect cells, count, and add CTL cell culture medium to a cell density of 0.5×10 6 / ml.
[0055] Co-culture of Non-CD8 PBMC cells (loaded with lung cancer antigen peptide) and CTL: According to the calculation formula Non-CD8 PBMC cell number = CTL cell number × 0.1 / CD14 expression percentage in Non-CD8 PBMC cells, take the required number of Non-CD8 PBMC cells (loaded with lung cancer antigen peptide) and co-culture with CTL cells, add IL-2 (final concentration 20 IU / ml) and IL-7 (final concentration 30 U / ml). Culture in a 37°C, 5% CO2 incubator.
[0056] (h) Cell culture medium replacement
[0057] On Day 9 and Day 12, cells were collected and counted, and CTL cell culture medium was added to a cell density of 0.5 × 10 6 / ml, add IL-2 (final concentration 20IU / ml) and IL-7 (final concentration 30U / ml), and culture in a 37°C, 5% CO2 incubator.
[0058] (i) Day 14, collection of CTL cells
[0059] 1.3 CTL detection
[0060] (a) CTLs were collected on Day 14 and counted using trypan blue staining.
[0061] (b) FACS detected cell phenotypes, including: CD3+, CD8+, CD3+CD8+CD56-, CD95-CD45RA+CD27+CCR7+, CD95+CD45RA+CD27+CCR7+, CD95+CD45RA-CD27+CCR7+, CD95+CD45RA-CD27-CCR7-, CD95+CD45RA+CD27-CCR7-.
[0062] (c) Killing experiments and detection
[0063] Killing medium: 2% FBS + 98% CTS TM AIM-V TM Medium.
[0064] Preparation of T2 cells (loaded with lung cancer antigen peptide): Add killing medium to adjust the cell density to 1×10 6 / mL, 8 lung cancer antigen peptides were added at a final concentration of 1 μg / ml, and incubated at 37°C for 2 h.
[0065] CTL cells and T2 cell control wells: the cell density was 1×10 6 / mL, 100 μl of cells were inoculated into each well of a 96-well U-shaped plate, and 100 μl of killing medium was added.
[0066] Co-culture of T2 cells (loaded with lung cancer antigen peptides) and CTL cells: 100 μl of T2 cells (cell density 1×10 6 / mL) and 100 μl CTL cells (cell density 1×10 6 / mL) were co-cultured in a 96-well U-shaped plate at a ratio of 1:1. The 96-well U-shaped plate was placed in a 37°C, 5% CO2 incubator for 20 hours. The 96-well U-shaped plate was centrifuged and the supernatant was collected. The ELISA kit was used to detect the concentration of IFN-γ in the supernatant.
[0067] 1.4 Test results
[0068] (a) Cell growth curve
[0069] Record the number of cells each time the medium is changed and draw a cell growth curve, such as Figure 1.1 shown.
[0070] (b) Cell phenotype
[0071] FACS test results, such as Figure 1.2 shown.
[0072] (c) CTL cells kill target cells
[0073] The ELISA kit was used to detect the concentration of IFN-γ in the culture medium after co-culture of CTL cells and target cells. Figure 1.3 shown.
[0074] 2. The co-culture ratio of CD8 cells and D1120 cells (loaded with lung cancer antigen peptide) on Day 0 is 10:1
[0075] Day0 CD8 cells and D1120 cells (loaded with lung cancer antigen peptides) were co-cultured at ratios of 20:1, 10:1, and 5:1, respectively. The CTL cells with a ratio of 10:1 had the best proliferation multiples, cell viability, percentage of CD95+CD45RA-CD27-CCR7- expression, and killing effect on T2 cells (loaded with lung cancer antigen peptides) and H1299-A2 cells.
[0076] 2.1 Preparation of cells and peptides
[0077] Same as 1.1.
[0078] 2.2 Experimental procedures
[0079] (a) Day 0, isolation of CD8 cells and purity analysis
[0080] PBMCs were isolated from normal human blood using Ficoll, and FACS assay determined that HLA-A2 expression was above 50%. CD8 cells and Non-CD8 PBMC cells were separated using magnetic beads coupled to anti-human CD8 antibodies, and three Non-CD8 PBMC cells were frozen. FACS assay showed that the percentage of CD14+ expression in Non-CD8 PBMC cells was 8.70%, and the percentages of CD3+, CD8+, CD3+CD8+CD56-, CD95-CD45RA+CD27+CCR7+, CD95+CD45RA+CD27+CCR7+, CD95+CD45RA-CD27+CCR7+, CD95+CD45RA-CD27+CCR7-, CD95+CD45RA+CD27-CCR7- in CD8 cells were 91.9%, 99.6%, 91.0%, 30.7%, 0%, 0%, 0%, 0%, 0%, respectively.
[0081] (b) Day 0, incubation of D1120 cells and lung cancer antigen peptides
[0082] Thaw frozen D1120 working cells and add Expressive Five SFM to a cell density of 1×10 7 / ml, added 8 lung cancer antigen peptides with a final concentration of 0.1μg / ml and β2M protein with a final concentration of 5μg / ml, and incubated at room temperature for 2h.
[0083] (c) Day 0, co-culture of CD8 cells and D1120 cells (loaded with lung cancer antigen peptide)
[0084] CD8 cells and D1120 cells (loaded with lung cancer antigen peptides) were co-cultured at different ratios (including 20:1, 10:1, and 5:1, with the same group name), and CTL cell culture medium was added until the CD8 cell density reached 3.3×106 / ml, cultured in a 37°C, 5% CO2 incubator for 5 days.
[0085] (d) Day 5, addition of IL-2 and IL-7
[0086] IL-2 (final concentration 20 IU / ml) and IL-7 (final concentration 30 U / ml) were added and cultured in a 37°C, 5% CO2 incubator.
[0087] (e) Day 7 and Day 14 (2 times of Non-CD8 cell stimulation)
[0088] Day7 Inactivation of Non-CD8 PBMC cells: Resuscitate 1 tube of Non-CD8 PBMC cells, add RPMI Medium Modified to resuspend the cells, centrifuge and change the medium, wash twice. Add CTL cell culture medium to a cell density of 5×10 6 / ml, add mitomycin at a final concentration of 10μg / ml, incubate at 37℃ for 20min, resuspend the cells in RPMI Medium Modified, centrifuge to change the medium, and wash three times.
[0089] Incubation of non-CD8 PBMC cells with antigen peptides: Add CTL cell culture medium to a cell density of 1×10 7 / ml, added 8 lung cancer antigen peptides with a final concentration of 5μg / ml and β2M protein with a final concentration of 5μg / ml, and incubated at 37℃ for 1.5h.
[0090] Day14 Treatment of Non-CD8 PBMC cells: Resuscitate 2 tubes of Non-CD8 PBMC cells, and other steps are the same as Day7.
[0091] CTL cell medium replacement: On Day 7, collect cells and culture medium and count them. 6 / mL was resuspended in culture medium, with 1 / 3 of the culture medium being the collected culture medium and 2 / 3 being fresh CTL cell culture medium. On Day 14, cells were collected, counted, and CTL cell culture medium was added to a cell density of 2×10 6 / ml.
[0092] Co-culture of Non-CD8 PBMC cells (loaded with lung cancer antigen peptide) and CTL cells: According to the calculation formula Non-CD8 PBMC cell number = CTL cell number × 0.1 / CD14 expression percentage in Non-CD8 PBMC cells, take the required number of Non-CD8 PBMC cells (loaded with lung cancer antigen peptide) and CTL for co-culture, add IL-2 (final concentration 20 IU / ml) and IL-7 (final concentration 30 U / ml). Culture in a 37°C, 5% CO2 incubator.
[0093] (f) Cell culture medium replacement
[0094] On Day 9, cells were collected, counted, and CTL cell culture medium was added to a cell density of 1.5 × 10 6 / ml, add IL-2 (final concentration 20IU / ml) and IL-7 (final concentration 30U / ml), and culture in a 37°C, 5% CO2 incubator.
[0095] The cells were collected and counted on Day 12, Day 16, and Day 18, and CTL cell culture medium was added to a cell density of 2×10 6 / ml, add IL-2 (final concentration 20IU / ml) and IL-7 (final concentration 30U / ml), and culture in a 37°C, 5% CO2 incubator.
[0096] (g) Day 20, collection of CTL cells
[0097] 2.3 CTL Detection
[0098] (a) CTLs were collected on Day 20 and counted using trypan blue staining to record the number of live and dead cells.
[0099] (b) FACS detected cell phenotypes, including: CD3+, CD8+, CD3+CD8+CD56-, CD95-CD45RA+CD27+CCR7+, CD95+CD45RA+CD27+CCR7+, CD95+CD45RA-CD27+CCR7+, CD95+CD45RA-CD27-CCR7-, CD95+CD45RA+CD27-CCR7-.
[0100] (c) Killing experiments and detection
[0101] On Day 18, while changing the cell medium, take the required number of cells for killing experiment.
[0102] Killing medium: 2% FBS + 98% CTS TM AIM-V TM Medium.
[0103] Preparation of T2 cells (loaded with lung cancer antigen peptide): Add killing medium to adjust the cell density to 1×10 6 / mL, 8 lung cancer antigen peptides were added at a final concentration of 1 μg / ml, and incubated at 37°C for 2 h.
[0104] CTL cells, T2 cells, H1299 cells, H1299-A2 cells control wells: all with a cell density of 1×10 6 / mL, 100 μl per well was inoculated in a 96-well U-shaped plate, and 100 μl of killing medium was added.
[0105] Co-culture of H1299 cells, H1299-A2 cells, T2 cells (loaded with lung cancer antigen peptides) and CTL cells: 100 μl H1299 cells, H1299-A2 cells, T2 cells loaded with 8 lung cancer antigen peptides (cell density was 1×10 6 / mL) and 100 μl CTL cells (cell density 1×10 6 / mL) were co-cultured in a 96-well U-shaped plate at a ratio of 1:1.
[0106] The 96-well U-shaped plate was placed in a 37°C, 5% CO2 incubator for 20 h, and the supernatant was collected by centrifugation.
[0107] The concentration of IFN-γ in the supernatant was detected by ELISA kit.
[0108] 2.4 Test results
[0109] (a) Cell growth curve
[0110] Record the number of cells each time the medium is changed and draw a cell growth curve, such as Figure 2.1 shown.
[0111] (b) Cell viability
[0112] CTL cell viability, such as Figure 2.2 shown.
[0113] (c) Cell phenotype
[0114] FACS test results, such as Figure 2.3 shown.
[0115] (d) CTL cells kill target cells
[0116] The ELISA kit was used to detect the concentration of IFN-γ in the culture medium after co-culture of CTL cells and target cells. Figure 2.4 shown.
[0117] 3. The concentration of lung cancer antigen peptide loaded on D1120 cells on Day 0 is 0.1 μg / ml
[0118] The concentrations of lung cancer antigen peptides loaded on D1120 cells on Day 0 were 0.01μg / ml, 0.1μg / ml, and 1μg / ml, respectively. There were no significant differences in the final CTL cell viability, percentage of expression of different cell phenotypes, and the killing values of CTL cells against T2 cells (loaded with lung cancer antigen peptides). The proliferation multiple of CTL cells in the 1μg / ml group was slightly higher than that in the other two groups. However, only the killing value of CTL cells in the 0.1μg / ml group against T2 cells (PBS control) was less than 200pg / ml, indicating that nonspecific killing was small.
[0119] 3.1 Preparation of cells and peptides
[0120] Same as 2.1.
[0121] 3.2 Experimental procedures
[0122] (a) Day 0, isolation of CD8 cells and purity analysis
[0123] Human PBMCs were isolated from normal human blood using Ficoll, and FACS assay determined that HLA-A2 expression was above 50%. CD8 cells and Non-CD8 PBMC cells were separated using magnetic beads coupled to anti-human CD8 antibodies, and three Non-CD8 PBMC cells were frozen. FACS assay showed that the percentage of CD14+ expression in Non-CD8 PBMC cells was 18.27%, and the percentages of CD3+, CD8+, CD3+CD8+CD56-, CD95-CD45RA+CD27+CCR7+, CD95+CD45RA+CD27+CCR7+, CD95+CD45RA-CD27+CCR7+, CD95+CD45RA-CD27+CCR7-, CD95+CD45RA+CD27-CCR7- in CD8 cells were 93.98%, 95.34%, 93.93%, 0%, 0%, 0%, 0%, 0%, 0%, 0%, respectively.
[0124] (b) Day 0, incubation of D1120 cells with different concentrations of lung cancer antigen peptides
[0125] Thaw the frozen D1120 working cells and add Expressive Five SFM to adjust the cell density to 1×10 7 / ml, D1120 cells were divided into 3 groups, and 8 lung cancer antigen peptides with different final concentrations (the final concentrations were 0.01μg / ml, 0.1μg / ml, 1μg / ml, and the group names were consistent) and β2M protein with a final concentration of 5μg / ml were added and incubated at room temperature for 2h.
[0126] (c) Day 0, co-culture of CD8 cells and D1120 cells (loaded with lung cancer antigen peptide)
[0127] The three groups of CD8 cells and D1120 cells (loaded with lung cancer antigen peptides) were co-cultured at a ratio of 10:1, and CTL cell culture medium was added to adjust the CD8 cell density to 3.3×10 6 / ml, with 2 replicates in each group, and cultured in a 37°C, 5% CO2 incubator for 5 days.
[0128] (d) Day 5, addition of IL-2 and IL-7
[0129] Same as 2.2.
[0130] (e) Day 7 and Day 14 (2 times of Non-CD8 PBMC cell stimulation)
[0131] Same as 2.2.
[0132] (f) Cell culture medium replacement
[0133] Same as 2.2.
[0134] (g) Day 20, collection of CTL cells
[0135] 3.3 Detection of CTL
[0136] (a) CTLs were collected on Day 20 and counted using trypan blue staining to record the number of live and dead cells.
[0137] (b) FACS detected cell phenotypes, including: CD3+, CD8+, CD3+CD8+CD56-, CD95-CD45RA+CD27+CCR7+, CD95+CD45RA+CD27+CCR7+, CD95+CD45RA-CD27+CCR7+, CD95+CD45RA-CD27-CCR7-, CD95+CD45RA+CD27-CCR7-.
[0138] (c) Killing experiments and detection
[0139] On Day 18, while changing the cell medium, take the required number of cells for killing experiment.
[0140] Killing medium: 2% FBS + 98% CTS TM AIM-V TM Medium.
[0141] Preparation of T2 cells (loaded with lung cancer antigen peptide): Add killing medium to adjust the cell density to 1×10 6 / mL, 8 lung cancer antigen peptides were added at a final concentration of 1 μg / ml, and incubated at 37°C for 2 h.
[0142] Preparation of T2 cells (PBS control): Add killing medium to adjust the cell density to 1×106 / mL, add PBS buffer with a volume equal to the total volume of the above 8 antigen peptides, and incubate at 37°C for 2h.
[0143] CTL cells and T2 cell control wells: according to the cell density of 1×10 6 / mL, 100 μl per well was inoculated in a 96-well U-shaped plate, and 100 μl of killing medium was added.
[0144] Co-culture of T2 cells (PBS control), T2 cells (loaded with lung cancer antigen peptides) and CTL cells: T2 cells (PBS control) and T2 cells (loaded with lung cancer antigen peptides) were cultured at 100 μl per well, 1×10 6 / mL of cells were mixed with 100 μl of CTL cells (cell density 1×10 6 / mL) were co-cultured in a 96-well U-shaped plate at a ratio of 1:1.
[0145] The 96-well U-shaped plate was placed in a 37°C, 5% CO2 incubator for 20 h, and the supernatant was collected by centrifugation.
[0146] The concentration of IFN-γ in the supernatant was detected by ELISA kit.
[0147] 3.4 Test results
[0148] (a) Cell growth curve
[0149] Record the number of cells each time the medium is changed and draw a cell growth curve, such as Figure 3.1 shown.
[0150] (b) Cell viability
[0151] CTL cell viability, such as Figure 3.2 shown.
[0152] (c) Cell phenotype
[0153] FACS test results, such as Figure 3.3 shown.
[0154] (d) CTL cells kill target cells
[0155] The ELISA kit was used to detect the concentration of IFN-γ in the culture medium after co-culture of CTL cells and target cells. Figure 3.4 shown.
[0156] 4. On Day 7 and Day 14, the concentration of lung cancer antigen peptide loaded on Non-CD8 PBMC cells was 1 μg / ml
[0157] The concentrations of lung cancer antigen peptide loaded on Non-CD8 PBMC cells on Day7 and Day14 were 1μg / ml, 5μg / ml, and 10μg / ml, respectively. The final CTL cell viability, percentage of expression of different cell phenotypes, and CTL cell killing of T2 (loaded lung cancer antigen peptide) showed no significant differences. Among them, the CTL cells in the 5μg / ml group proliferated slightly more, but compared with the killing values of CTL cells against T2 cells (PBS control), the CTL cells in the 1μg / ml group showed no obvious nonspecific killing, and the CTL cells in the 5μg / ml and 10μg / ml groups showed higher nonspecific killing values.
[0158] 4.1 Preparation of cells and peptides
[0159] Same as 2.1.
[0160] 4.2 Experimental procedures
[0161] (a) Day 0, isolation of CD8 cells and purity analysis
[0162] Human PBMCs were separated from normal human blood using Ficoll, and HLA-A2 expression was determined to be above 50% by FACS. CD8 cells and Non-CD8 PBMCs were separated using magnetic beads coupled with anti-human CD8 antibodies, and three tubes of Non-CD8 PBMCs were cryopreserved. FACS detected that the percentage of CD14+ expression in Non-CD8 PBMC cells was 1.34%, and the percentages of CD3+, CD8+, CD3+CD8+CD56-, CD95-CD45RA+CD27+CCR7+, CD95+CD45RA+CD27+CCR7+, CD95+CD45RA-CD27+CCR7+, CD95+CD45RA-CD27-CCR7-, and CD95+CD45RA+CD27-CCR7- in CD8 cells were 93.78%, 97.67%, 92.40%, 14.48%, 0%, 0%, 0%, and 0%, respectively.
[0163] (b) Day 0, incubation of D1120 cells and lung cancer antigen peptides
[0164] Same as 2.2.
[0165] (c) Day 0, co-culture of CD8 cells and D1120 cells (loaded with lung cancer antigen peptide)
[0166] CD8 cells and D1120 cells (loaded with lung cancer antigen peptides) were co-cultured at a ratio of 10:1, and CTL cell culture medium was added to adjust the CD8 cell density to 3.3×10 6 / ml, set up 3 groups, marked as 1μg / ml, 5μg / ml, 10μg / ml, 2 replicate wells in each group. Cultured in a 37℃, 5% CO2 incubator for 5 days.
[0167] (d) Day 5, addition of IL-2 and IL-7
[0168] Same as 2.2.
[0169] (e) Day 7 and Day 14 (2 times of Non-CD8 PBMC cell stimulation)
[0170] Day7 Inactivation treatment of Non-CD8 PBMC cells: Same as 2.2.
[0171] Incubation of Non-CD8 PBMC cells with antigen peptides: Take the required number of Non-CD8 PBMC cells, a total of 3 groups, add CTL cell culture medium to a cell density of 1×10 7 / ml, 8 lung cancer antigen peptides with different final concentrations (final concentrations of 1μg / ml, 5μg / ml, 10μg / ml) and β2M protein with a final concentration of 5μg / ml were added respectively, and incubated at 37℃ for 1.5h.
[0172] Day14 Treatment of Non-CD8 PBMC cells: Resuscitate 2 tubes of Non-CD8 cells, and other steps are the same as Day7.
[0173] CTL cell medium replacement: same as 2.2.
[0174] Co-culture of non-CD8 PBMC cells (loaded with lung cancer antigen peptides) and CTL cells: Same as 2.2.
[0175] (f) Cell culture medium replacement
[0176] Same as 2.2.
[0177] (g) Day 20, collection of CTL cells
[0178] 4.3 Detection of CTL
[0179] Same as 3.3.
[0180] 4.4 Test results
[0181] (a) Cell growth curve
[0182] Record the number of cells each time the medium is changed and draw a cell growth curve, such as Figure 4.1 shown.
[0183] (b) Cell viability
[0184] CTL cell viability, such as Figure 4.2 shown.
[0185] (c) Cell phenotype
[0186] FACS test results, such as Figure 4.3 shown.
[0187] (d) CTL cells kill target cells
[0188] The ELISA kit was used to detect the concentration of IFN-γ in the culture medium after co-culture of CTL cells and target cells. Figure 4.4 shown.
[0189] 5. On Day 7 and Day 14, non-CD8 PBMC cells treated with non-MMC were used to stimulate T cell expansion
[0190] Comparing the CTL preparation experiments with Non-CD8 PBMC cells treated with or without MMC on Day 7 and Day 14, there were no significant differences in the CTL cell proliferation times, cell viability, percentage of expression of different cell phenotypes, and the killing value of CTL cells against T2 cells (loaded with lung cancer antigen peptides).
[0191] 5.1 Preparation of cells and peptides
[0192] Same as 4.1.
[0193] 5.2 Experimental procedures
[0194] (a) Day 0, isolation of CD8 cells and purity analysis
[0195] Human PBMCs were separated from normal human blood using Ficoll, and HLA-A2 expression was determined to be above 50% by FACS. CD8 cells and Non-CD8 PBMCs were separated using anti-human CD8 antibody OUC magnetic beads, and three tubes of Non-CD8 PBMCs were frozen. FACS detected that the percentage of CD14+ expression in Non-CD8 PBMC cells was 5.23%, and the percentages of CD3+, CD8+, CD3+CD8+CD56-, CD95-CD45RA+CD27+CCR7+, CD95+CD45RA+CD27+CCR7+, CD95+CD45RA-CD27+CCR7+, CD95+CD45RA-CD27-CCR7-, and CD95+CD45RA+CD27-CCR7- in CD8 cells were 98.27%, 98.48%, 96.63%, 33.31%, 0%, 0%, 0%, and 0%, respectively.
[0196] (b) Day 0, incubation of D1120 cells and lung cancer antigen peptides
[0197] Same as 4.2.
[0198] (c) Day 0, co-culture of CD8 cells and D1120 cells (loaded with lung cancer antigen peptide)
[0199] CD8 cells and D1120 cells (loaded with lung cancer antigen peptides) were co-cultured at a ratio of 10:1, and CTL cell culture medium was added to adjust the CD8 cell density to 3.3×10 6 / ml, set up 2 groups, marked as MMC-added group and MMC-unadded group, with 2 replicate wells in each group. Cultured in a 37°C, 5% CO2 incubator for 5 days.
[0200] (d) Day 5, addition of IL-2 and IL-7
[0201] Same as 4.2.
[0202] (e) Day 7 and Day 14 (2 times of Non-CD8 PBMC cell stimulation)
[0203] Day 7 Treatment of Non-CD8 PBMC cells in the MMC group: Resuscitate one tube of Non-CD8 PBMC cells, add RPMI Medium Modified to resuspend the cells, centrifuge and change the medium, wash twice, take the required number of cells and mark them as Non-CD8 PBMC cells in the MMC group and Non-CD8 PBMC cells in the non-MMC group. Add CTL cell culture medium to the Non-CD8 PBMC cells in the MMC group to a cell density of 5×10 6 / ml, then add mitomycin at a final concentration of 10μg / ml, and place at 37℃ for 20min. Resuspend the cells in RPMI Medium Modified, centrifuge and change the medium, and wash 3 times. Add CTL cell culture medium to a cell density of 1×10 7 / ml, added 8 lung cancer antigen peptides with a final concentration of 5μg / ml and β2M protein with a final concentration of 5μg / ml, and incubated at 37℃ for 1.5h.
[0204] Day 7 Treatment of Non-CD8 PBMC cells in the group without MMC: Take the Non-CD8 PBMC cells in the group without MMC and add CTL cell culture medium to a cell density of 1×10 7 / ml, added 8 lung cancer antigen peptides with a final concentration of 5μg / ml and β2M protein with a final concentration of 5μg / ml, and incubated at 37℃ for 1.5h.
[0205] Day14 Treatment of Non-CD8 PBMC cells: Resuscitate 2 tubes of Non-CD8 PBMC cells, and other steps are the same as Day7.
[0206] CTL cell medium replacement: same as 4.2.
[0207] Co-culture of non-CD8 PBMC cells (loaded with lung cancer antigen peptides) and CTL cells: Same as 4.2.
[0208] (f) Cell culture medium replacement
[0209] Same as 4.2.
[0210] (g) Day 20, collection of CTL cells
[0211] 5.3 Detection of CTL
[0212] Same as 4.3.
[0213] 5.4 Test results
[0214] (a) Cell growth curve
[0215] Record the number of cells each time the medium is changed and draw a cell growth curve, such as Figure 5.1 shown.
[0216] (b) Cell viability
[0217] CTL cell viability, such as Figure 5.2 shown.
[0218] (c) Cell phenotype
[0219] FACS test results, such as Figure 5.3 shown.
[0220] (d) CTL cells kill target cells
[0221] The ELISA kit was used to detect the concentration of IFN-γ in the culture medium after co-culture of CTL cells and target cells. Figure 5.4 shown.
[0222] 6. The final concentration of added IL-2 is 20IU / ml
[0223] Three groups of IL-2 with different final concentrations (10IU / ml, 20IU / ml, 40IU / ml) were used for CTL preparation experiments. There were no significant differences in the final percentage of CTL cell CD3+CD8+CD56- expression, the percentage of CD95+CD45RA-CD27-CCR7- expression, and the killing of T2 cells (loaded with lung cancer antigen peptide) by CTL cells among the three groups. However, the CTL cell viability and CTL cell proliferation multiples were the highest in the 20IU / ml group.
[0224] 6.1 Preparation of cells and peptides
[0225] Same as 5.1.
[0226] 6.2 Experimental procedures
[0227] (a) Day 0, isolation of CD8 cells and purity analysis
[0228] Human PBMCs were separated from normal human blood using Ficoll, and HLA-A2 expression was determined to be above 50% by FACS. CD8 cells and Non-CD8 PBMCs were separated using magnetic beads coupled with anti-human CD8 antibodies, and three tubes of Non-CD8 PBMCs were cryopreserved. FACS detected that the percentage of CD14+ expression in Non-CD8 PBMC cells was 5.32%, and the percentages of CD3+, CD8+, CD3+CD8+CD56-, CD95-CD45RA+CD27+CCR7+, CD95+CD45RA+CD27+CCR7+, CD95+CD45RA-CD27+CCR7+, CD95+CD45RA-CD27-CCR7-, and CD95+CD45RA+CD27-CCR7- in CD8 cells were 87.54%, 95.27%, 85.69%, 30.61%, 0%, 0%, 0%, and 0%, respectively.
[0229] (b) Day 0, incubation of D1120 cells and lung cancer antigen peptides
[0230] Same as 5.2.
[0231] (c) Day 0, co-culture of CD8 cells and D1120 cells (loaded with lung cancer antigen peptide)
[0232] CD8 cells and D1120 cells (loaded with lung cancer antigen peptides) were co-cultured at a ratio of 10:1, and CTL cell culture medium was added to adjust the CD8 cell density to 3.3×10 6 / ml, set up 3 groups, marked as 10IU / ml, 20IU / ml, 40IU / ml, 2 replicate wells in each group. Cultured in a 37°C, 5% CO2 incubator for 5 days.
[0233] (d) Day 5, addition of IL-2 and IL-7
[0234] The three groups of 10 IU / ml, 20 IU / ml and 40 IU / ml were added with different final concentrations of IL-2 (final concentration 10 IU / ml, 20 IU / ml and 40 IU / ml) and IL-7 (final concentration 30 U / ml) respectively, and cultured in a 37°C, 5% CO2 incubator.
[0235] (e) Day 7 and Day 14 (2 times of Non-CD8 PBMC cell stimulation)
[0236] Day7 Treatment of Non-CD8 PBMC cells: Resuscitate 1 tube of Non-CD8 PBMC cells, add RPMI Medium Modified to resuspend the cells, centrifuge and change the medium, wash twice, take the required number of cells and add CTL cell culture medium to a cell density of 1×10 7 / ml, added 8 lung cancer antigen peptides with a final concentration of 5μg / ml and β2M protein with a final concentration of 5μg / ml, and incubated at 37℃ for 1.5h.
[0237] Day14 Treatment of Non-CD8 PBMC cells: Resuscitate 2 tubes of Non-CD8 PBMC cells, and other steps are the same as Day7.
[0238] CTL cell medium replacement: same as 5.2.
[0239] Co-culture of Non-CD8 PBMC cells (loaded with lung cancer antigen peptide) and CTL cells: According to the calculation formula Non-CD8 PBMC cell number = CTL cell number × 0.1 / CD14 expression percentage in Non-CD8 PBMC cells, the required number of Non-CD8 PBMC cells (loaded with lung cancer antigen peptide) and CTL cells were co-cultured, and different final concentrations of IL-2 (final concentration 10IU / ml, 20IU / ml, 40IU / ml) and IL-7 (final concentration 30U / ml) were added to the 10IU / ml, 20IU / ml, and 40IU / ml groups, respectively. Culture in a 37°C, 5% CO2 incubator.
[0240] (f) Cell culture medium replacement
[0241] On Day 9, cells were collected, counted, and CTL cell culture medium was added to a cell density of 1.5 × 10 6 / ml, 10IU / ml, 20IU / ml, 40IU / ml groups were added with different final concentrations of IL-2 (final concentration 10IU / ml, 20IU / ml, 40IU / ml) and IL-7 (final concentration 30U / ml), respectively, and cultured in a 37°C, 5% CO2 incubator.
[0242] On Day 12, Day 16, and Day 18, cells were collected, counted, and CTL cell culture medium was added to a cell density of 2×10 6 / ml, 10IU / ml, 20IU / ml, 40IU / ml groups were added with different final concentrations of IL-2 (final concentration 10IU / ml, 20IU / ml, 40IU / ml) and IL-7 (final concentration 30U / ml), respectively, and cultured in a 37°C, 5% CO2 incubator.
[0243] (g) Day 20, collection of CTL cells
[0244] 6.3 Detection of CTL
[0245] Same as 5.3.
[0246] 6.4 Test results
[0247] (a) Cell growth curve
[0248] Record the number of cells each time the medium is changed and draw a cell growth curve, such as Figure 6.1 shown.
[0249] (b) Cell viability
[0250] CTL cell viability, such as Figure 6.2 shown.
[0251] (c) Cell phenotype
[0252] FACS test results, such as Figure 6.3 shown.
[0253] (d) CTL cells kill target cells
[0254] The ELISA kit was used to detect the concentration of IFN-γ in the culture medium after co-culture of CTL cells and target cells. Figure 6.4 shown.
[0255] 7. The final concentration of added IL-7 is 30U / ml
[0256] Three groups of IL-7 with different final concentrations (15U / ml, 30U / ml, 60U / ml) were used for CTL preparation experiments. The final CTL cell viability, the percentage of different phenotype expressions (CD3+CD8+CD56-, CD95-CD45RA+CD27+CCR7+, CD95+CD45RA+CD27+CCR7+, CD95+CD45RA-CD27+CCR7+), and the killing results of CTL cells against T2 (antigen peptide incubation) were not significantly different. However, the CTL cell proliferation times and the percentage of CD95+CD45RA-CD27-CCR7- expression in the 30U / ml group and the 60U / ml group were higher than those in the 15U / ml group, while there was no significant difference between the 30U / ml group and the 60U / ml group, so 30U / ml was confirmed to be the optimal final concentration.
[0257] 7.1 Preparation of cells and peptides
[0258] Same as 6.1.
[0259] 7.2 Experimental procedures
[0260] (a) Day 0, isolation of CD8 cells and purity analysis
[0261] Human PBMCs were separated from normal human blood using Ficoll, and HLA-A2 expression was determined to be above 50% by FACS. CD8 cells and Non-CD8 PBMCs were separated using magnetic beads coupled with anti-human CD8 antibodies, and three tubes of Non-CD8 PBMCs were cryopreserved. FACS detected that the percentage of CD14+ expression in Non-CD8 PBMC cells was 9.29%, and the percentages of CD3+, CD8+, CD3+CD8+CD56-, CD95-CD45RA+CD27+CCR7+, CD95+CD45RA+CD27+CCR7+, CD95+CD45RA-CD27+CCR7+, CD95+CD45RA-CD27-CCR7-, and CD95+CD45RA+CD27-CCR7- in CD8 cells were 86.43%, 94.09%, 84.13%, 56.10%, 0%, 0%, 0%, and 0%, respectively.
[0262] (b) Day 0, incubation of D1120 cells and lung cancer antigen peptides
[0263] Same as 6.2.
[0264] (c) Day 0, co-culture of CD8 cells and D1120 cells (loaded with lung cancer antigen peptide)
[0265] CD8 cells and D1120 cells (loaded with lung cancer antigen peptides) were co-cultured at a ratio of 10:1, and CTL cell culture medium was added to adjust the CD8 cell density to 3.3×10 6 / ml, set up 3 groups, marked as 15U / ml, 30U / ml, 60U / ml, 2 replicate wells in each group, and cultured in a 37°C, 5% CO2 incubator for 5 days.
[0266] (d) Day 5, addition of IL-2 and IL-7
[0267] The three groups of 15U / ml, 30U / ml and 60U / ml were added with different final concentrations of IL-7 (final concentration 15U / ml, 30U / ml, 60U / ml) and IL-2 (final concentration 20IU / ml), respectively, and cultured in a 37°C, 5% CO2 incubator.
[0268] (e) Day 7 and Day 14 (2 times of Non-CD8 PBMC cell stimulation)
[0269] Day 7 and Day 14 Non-CD8 PBMC cell treatment: 8 lung cancer antigen peptides were added at a final concentration of 1 μg / ml, and the rest of the steps were the same as 6.2.
[0270] CTL cell medium replacement: same as 6.2.
[0271] Co-culture of Non-CD8 PBMC cells (loaded with lung cancer antigen peptide) and CTL cells: According to the calculation formula Non-CD8 PBMC cell number = CTL cell number × 0.1 / CD14 expression percentage in Non-CD8 PBMC cells, the required number of Non-CD8 PBMC cells (loaded with lung cancer antigen peptide) and CTL cells were co-cultured, and different final concentrations of IL-7 (final concentration 15U / ml, 30U / ml, 60U / ml) and IL-2 (final concentration 20IU / ml) were added to the 15U / ml, 30U / ml, and 60U / ml groups, respectively. Culture in a 37°C, 5% CO2 incubator.
[0272] (f) Cell culture medium replacement
[0273] On Day 9, cells were collected, counted, and CTL cell culture medium was added to a cell density of 1.5 × 10 6 / ml, 15U / ml, 30U / ml, 60U / ml groups were added with different final concentrations of IL-7 (final concentration 15U / ml, 30U / ml, 60U / ml) and IL-2 (final concentration 20IU / ml), respectively, and cultured in a 37°C, 5% CO2 incubator.
[0274] On Day 12, Day 16, and Day 18, cells were collected, counted, and CTL cell culture medium was added to a cell density of 2×10 6 / ml, 15U / ml, 30U / ml, 60U / ml groups were added with different final concentrations of IL-7 (final concentration 15U / ml, 30U / ml, 60U / ml) and IL-2 (final concentration 20IU / ml), respectively, and cultured in a 37°C, 5% CO2 incubator.
[0275] (g) Day 20, collection of CTL cells
[0276] 7.3 Detection of CTL
[0277] Same as 6.3.
[0278] 7.4 Test results
[0279] (a) Cell growth curve
[0280] Record the number of cells each time the medium is changed and draw a cell growth curve, such as Figure 7.1 shown.
[0281] (b) Cell viability
[0282] CTL cell viability, such as Figure 7.2 shown.
[0283] (c) Cell phenotype
[0284] FACS test results, such as Figure 7.3 shown.
[0285] (d) CTL cells kill target cells
[0286] The ELISA kit was used to detect the concentration of IFN-γ in the culture medium after co-culture of CTL cells and target cells. Figure 7.4 shown.
[0287] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.
Claims
1. A process for preparing tumor-specific CTL cells, characterized in that Here’s how: D0, prepare artificial antigen presenting cells D1120 from the established working cell bank, and magnetically sort CD8 cells and Non-CD8 PBMC cells from human peripheral blood mononuclear cells; D0, co-incubating artificial antigen presenting cells D1120 and lung cancer antigen peptides to obtain artificial antigen presenting cells D1120 loaded with lung cancer antigen peptides; D0-D4, co-culturing CD8 cells and artificial antigen presenting cells D1120 loaded with lung cancer antigen peptides; D5, adding IL-2 and IL-7; On D7 and D14, the co-cultured CD8 cells contain CTL cells, the CTL cells are collected, and co-cultured with Non-CD8 PBMC cells loaded with lung cancer antigen peptides for restimulation, wherein the Non-CD8 PBMC cells loaded with lung cancer antigen peptides are obtained by incubating Non-CD8 PBMC cells with lung cancer antigen peptides; D7-D20, during cell expansion, the cell medium was changed, and IL-2 and IL-7 were added to maintain their growth; D20, collect CTL cells after restimulation and expansion culture, stain and count, and record the number of live cells and dead cells; The sequence of the lung cancer antigen peptide is: SLLMWITQCFL, RMFPNAPYL, FLWGPRALV, KMVELVHFL, SLLMWITQV, ILAKFLHWL, YLQLVFGIEV and SLLMWITQC; The artificial antigen presenting cell D1120 is based on Drosophila SC2, and is co-transfected to express human HLA-A2, CD80, CD54, CD70 and LFA-3 molecules, and the expression of the molecules is all above 50%.
2. A process for preparing tumor-specific CTL cells as claimed in claim 1, characterized in that HLA-A2 expression in the human peripheral blood mononuclear cells exceeds 50%.
3. A process for preparing tumor-specific CTL cells as claimed in claim 1, characterized in that The ratio of CD8 cells and artificial antigen-presenting cells D1120 loaded with lung cancer antigen peptides to be co-cultured from D0 to D4 was 10:
1.
4. A process for preparing tumor-specific CTL cells as claimed in claim 1, characterized in that No IL-2 was added from D0 to D4.
5. A process for preparing tumor-specific CTL cells according to claim 3, characterized in that The concentration of lung cancer antigen peptide loaded on D0-D4 artificial antigen presenting cells was 1 μg / ml.
6. A process for preparing tumor-specific CTL cells according to claim 1, characterized in that The lung cancer antigen peptide concentration loaded on Non-CD8 PBMC cells for restimulation on D7 and D14 was 1 μg / ml.
7. A process for preparing tumor-specific CTL cells according to claim 6, characterized in that Non-CD8 PBMCs were restimulated on D7 and D14 without treatment with mitomycin.
8. A process for preparing tumor-specific CTL cells as claimed in claim 1, characterized in that The final concentration of IL-2 added on D5 was 20 IU / ml.
9. A process for preparing tumor-specific CTL cells as claimed in claim 1, characterized in that The final concentration of IL-7 added on D5 was 30 U / ml.
10. A process for preparing tumor-specific CTL cells as claimed in claim 1, characterized in that During cell expansion from D7 to D20, IL-2 was added at a concentration of 20 IU / ml to maintain T cell growth.
11. A process for preparing tumor-specific CTL cells as claimed in claim 1, characterized in that During D7-D20 cell expansion, IL-7 was added at a concentration of 30 U / ml to maintain T cell growth.
